Exemplar Genetics Logo Accredited By: AAALAC - Where Science and Response
 
Announcement

CFTR-/- and
CFTR F508del/F508del
PIGS and TISSUES NOW AVAILABLE!

Click Here for more information

Latest News

EXEMPLAR GENETICS EMPLOYEES ASSIST DES MOINES FAMILIES AFFECTED BY MUSCULAR DYSTROPHY 
Exemplar Genetics employees, their families, friends and a local contractor volunteered their time, energy and resources to build a wheelchair ramp at the home of a young woman with muscular dystrophy and assist another family affected by the life-robbing disease.
READ MORE


EXEMPLAR GENETICS RECOGNIZED AS LIFE SCIENCE COMPANY IN TECHONOLOGY ASSOCIATION OF IOWA AWARDS
Exemplar Genetics was selected as the Life Sciences Company of the Year in tonight’s Technology Association of Iowa’s annual awards to recognize extraordinary achievements by the state’s high-tech businesses and individuals.
READ MORE


EXEMPLAR GENETICS SELECTED AS FINALIST FOR BREAKOUT BUSINESS, LIFE SCIENCE COMPANY, TECH FIRM OF YEAR IN TECHONOLOGY ASSOCIATION OF IOWA AWARDS
Exemplar Genetics is a finalist in three categories of the Technology Association of Iowa’s annual awards to celebrate extraordinary achievements among high-tech businesses and individuals.
READ MORE

 

 

Discovery drives the human race
to new heights each day.

Explorers in all fields have made our lives and world better through their courage to venture into new frontiers and beyond. Yet, their ability to discover has always relied on the proper vehicle to propel them from theory to reality. At Exemplar Genetics, we enable discovery by providing the vehicle to break new ground on the medical research frontier.

Exemplar Genetics Sign Until now, researchers have lacked animal models that faithfully represent human diseases. As a result, a sizeable barrier has blocked progress in the discovery of human disease mechanisms; novel diagnostics, procedures, devices, prevention strategies and therapeutics; and the ability to predict in humans the efficacy of those next-generation procedures, devices, and therapeutics.

Advances in molecular genetics and the Human Genome Project have given mankind a promising window into the genes that cause and/or predispose humans to various diseases. Improved methods to modify specific genes in mice have led to significant advances. Yet, mouse models continue to hold limited value — and always will.

Exemplar Genetics bridges the considerable gap between the laboratory mouse and human testing with a patented process featuring a substantially improved animal model: the pig.

Pigs and humans share far more anatomical, histological, biochemical and physiologic properties than mice and humans. Pigs are excellent models for cardiovascular disease, obesity, diabetes, alcoholism, hypertension, cutaneous pharmacology and toxicology, lipoprotein metabolism, intestinal function, nutrition, and injury and repair. Pigs and humans also have similar immune systems and inflammatory responses.

Exemplar Genetics capitalizes on these characteristics and its expertise in specific gene modification to deliver a reliable model of human disease.

From model development to model delivery, our one-of-a-kind vertically integrated system — genetic modification laboratory to model production system — positions Exemplar Genetics to deliver the models that leading-edge researchers need in the quantities they require.


Exemplar Genetics stands uniquely ready to enable academic scientists, disease foundations, pharmaceutical companies and others in their quest to discover solutions to debilitating diseases because we provide a vehicle that no other company can offer.


While several firms offer normal pigs and “induced” pig models of disease, none represents direct competition today because no other gene-targeted, large animal models of human disease have been created. That gives Exemplar Genetics a significant advantage over this competition, especially with the diseases for which mouse models have been inadequate.

 


  AALAS & AAALAC International Logos

Site design and development by Creative Leap, Inc.